¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Leukemia, accelerated phase of"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • colostral phase
    ÃÊÀ¯±â, ùÁ¥¼·Ãë±â
  • compression phase
    ¾ÐÃà»ó
  • delayed sleep phase
    ¼ö¸éÀ§»óÁö¿¬
  • delayed sleep phase syndrome
    ¼ö¸éÀ§»óÁö¿¬ÁõÈıº
  • depressive phase
    ¿ì¿ï»ó
  • death phase
    »ç¸ê±â
  • diastolic phase
    È®Àå±â
  • disperse phase
    ºÐ»ê±â
  • diurnal phase
    ÁÖ°£»ó
  • expiratory phase
    È£±â»ó
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • exponential phase
    Áö¼öÁõ½Ä±â
  • ejection phase
    ¹ÚÃâ±â
  • equilibrium phase
    ÆòÇü±â
  • erythrocytic phase
    ÀûÇ÷±¸³»¹ßÀ°±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • phase contrast
    À§»ó´ëÁ¶
  • phase curve
    À§»ó°î¼±
  • death phase
    »ç¸ê±â
  • delayed sleep phase
    Áö¿¬¼ö¸éÀ§»ó
  • delayed sleep phase syndrome
    ¼ö¸éÀ§»óÁö¿¬ÁõÈıº
  • depressive phase
    ¿ì¿ï»ó
  • diastolic phase
    È®Àå±â, À̿ϱâ
  • diplotene phase
    °ã¼¶À¯±â
  • diurnal phase
    ÁÖ°£»ó
  • phase delay
    À§»óÁö¿¬
  • phase difference
    À§»óÂ÷
  • phase display
    À§»óÇ¥½Ã
  • phase encode direction
    À§»óºÎȣȭ¹æÇâ
  • ejection phase
    ¹ÚÃâ±â
  • equilibrium phase
    ÆòÇü±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • radiation leukemia
    ¹æ»ç¼±¹éÇ÷º´(Û¯ÞÒ Û¯ÞÒàÊÛÜúìÜ»)
  • 3D phase contrast angiography
    3Â÷¿ø À§»ó ´ëÁ¶ Ç÷°üÁ¶¿µ¼ú
  • DNA synthetic phase
    DNA ÇÕ¼º±â
  • Go phase
    Go±â
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â(Ê¥áÜÑ¢).
  • acute phase protein
    ±Þ¼ºº´±â´Ü¹éÁú
  • acute phase reactant
    ±Þ¼º±â ÀÛ¿ë¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ(¡­Ñ¢Úãëë)
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
  • acute phase serum
    ±Þ¼ºº´±âÇ÷û
  • acute phase substances
    ±Þ¼º±â ¹°Áú(ÐáàõÑ¢Úªòõ).
  • advanced sleep phase syndrome
    ÀüÁø¼º ¼ö¸éÀ§»ó ÁõÈıº
  • anal-sadistic phase
    Ç×¹®-°¡ÇÐ(½Ã)±â
  • arterial phase
    µ¿¸Æ±â
  • full erection phase
    ¿ÏÀü¹ß±â±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • chronic lymphocytic leukemia
    ¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸(¼º)¹éÇ÷º´(?Ë´ËÛËÑÌ´ËÓ).
  • chronic lymphocytic leukemia=CLL
    ¸¸¼º¸²ÇÁ±¸¼º¹éÇ÷º´
  • chronic myelogenous leukemia
    ¸¸¼º°ñ¼ö¼º ¹éÇ÷º´.
  • chronic myelogenous leukemia
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´
  • chronic myelogenous leukemia
    ¸¸¼º°ñ¼ö¼º ¹éÇ÷º´.
  • chronic myelomonocytic leukemia
    ¸¸¼º °ñ¼ö¼º ´Ü±¸¹éÇ÷º´
  • embryonal leukemia
    žƹéÇ÷º´, °£¼¼Æ÷¼º ¹éÇ÷º´(ÊÏá¬øààõÛÜúìÜ»).
  • eosinophilic leukemia
    È£»ê±¸¼º ¹éÇ÷º´.
  • feline leukemia virus
    °í¾çÀÌ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • feline leukemia virus
    °í¾çÀÌ ¹éÇ÷º´¹ÙÀÌ·¯½º
  • giant cell leukemia
    °Å¼¼Æ÷¹éÇ÷º´.
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´, Åм¼Æ÷¹éÇ÷º´
  • hairy cell leukemia
    Åм¼Æ÷ ¹éÇ÷º´
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • test phase
    ½ÃÇè±â
  • venous phase
    Á¤¸Æ»ó, Á¤¸Æ±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ATL Achilles tendon lengthening; acute T-cell leukemia; adult T-cell leukemia; anterior tricuspid leafle...
CLL cholesterol-lowering lipid; chronic lymphatic leukemia; chronic lymphocytic leukemia; cow lung lavag...
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
FL fatty liver; feline leukemia; femur length; fibers of Luschka; fibroblast-like; filtration leukapher...
FLV feline leukemia virus; Friend leukemia virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AP Acute-phase
ATPS Aqueous two-phase system
DSPS Delayed Sleep Phase Syndrome
DNAPL dense non-aqueous phase liquid
FPIR First-phase insulin response
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mitotic phase
    À¯»ç ºÐ¿­±â
  • phase 1 study
    ÀÓ»ó Á¦1»ó ½ÃÇè
  • phase artifact
    À§»ó Àΰø¹°
  • phase boundary
    »ó°è
  • phase coherence
    À§»ó °áÁý
  • phase contrast
    À§»ó ´ëÁ¶
  • phase curve
    À§»ó °î¼±
  • phase display
    À§»ó Ç¥½Ã
  • phase encoding
    À§»ó ºÎȣȭ
  • phase encoding step
    À§»ó ºÎÈ£ ´Ü°è
  • phase frequency swap
    À§»ó Á֯ļö ±³È¯
  • phase II treatment
    Á¦2´Ü°è Ä¡·á
  • phase mismapping
    À§»ó ¿ÀÁöµµ ÀÛ¼º
  • phase of meditation
    Àẹ ±â°£
  • phase ratio
    »óºñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
phase, resting More appropriately called interphase. The interval in the cell cycle between two cell divisions when the individual chromosomes cannot be distinguished, interphase was once thought to be the resting phase but it is far from a time of rest for the cell. It is the time when DNA is replicated in the cell nucleus.
(12 Dec 1998)
phase rule An expression of the relationships existing between systems in equilibrium: P + V = C + 2, where P is the number of phases, V the variance or degrees of freedom, and C the number of components; it also follows that the variance is, V = C + 2 -P. For H2O at its triple point, V = 1 + 2 -3 = 0, i.e., both temperature and pressure are fixed.
Synonym: Gibb's phase rule.
(05 Mar 2000)
phase separation <chemistry> The separation of fluid phases that contain different concentrations of common components.
Occurs with partially miscible solvents used in many biochemical separation methods. Also temperature dependent phase separation occurs with some detergent solutions. With reference to membranes means the segregation of lipid components into domains that have different chemical composition.
(31 Dec 1997)
phase shift <microscopy> A change in the phase relationship between two alternating quantities of the same frequency.
(05 Aug 1998)
phase variation <microbiology> Alteration in the expression of surface antigens by bacteria.
For example: Salmonella can express either of two forms of flagellin, H1 and H2, that are coded by different genes. Control of which form is expressed is brought about by inversion of the promoter for the H2 gene, which if functional (noninverted) is associated with the expression of H2 and the production of a repressor of the H1 gene.
Inversion occurs about every 1000 bacterial divisions and is under the control of another gene, hin, that is within the invertable sequence.
(31 Dec 1997)
chronic phase Refers to the early stages of chronic myelogenous leukaemia. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.
(12 Dec 1998)
microscopy, phase-contrast A form of interference microscopy in which variations of the refracting index in the object are converted into variations of intensity in the image. This is achieved by the action of a phase plate.
(12 Dec 1998)
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á